MIRM Stock Gets Increased EPS Forecast from HC Wainwright

Key Points

• HC Wainwright raised Mirum Pharmaceuticals’ Q1 2027 EPS forecast to $0.09 from $0.08 and projects full-year 2027 EPS of $1.42. The firm maintained its “Buy” rating and set a $195 price target.
• Mirum’s latest quarter showed a $1.06 per-share loss, missing the $0.74 consensus estimate, although revenue rose 37.9% year over year to $176.24 million and exceeded expectations.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus rating and average target price of $141.19, despite shares opening at $87.96 and trading below their 50- and 200-day moving averages.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Analysts at HC Wainwright increased their Q1 2027 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research note issued to investors on Monday, September 28th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.09 per share for the quarter, up from their previous forecast of $0.08. HC Wainwright has a "Buy" rating and a $195.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q2 2027 earnings at $0.18 EPS, Q4 2027 earnings at $0.80 EPS and FY2027 earnings at $1.42 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. During the same quarter in the previous year, the business earned ($0.12) EPS. The company's quarterly revenue was up 37.9% on a year-over-year basis.

MIRM has been the subject of several other research reports. Citigroup reissued a "market outperform" rating on shares of Mirum Pharmaceuticals in a report on Monday. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a report on Monday, June 15th. JPMorgan Chase & Co. boosted their target price on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an "overweight" rating in a research report on Thursday, July 2nd. Wall Street Zen lowered Mirum Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Sunday, September 6th. Finally, Morgan Stanley set a $144.00 price target on Mirum Pharmaceuticals in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $141.19.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $87.96 on Tuesday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. The stock has a market capitalization of $5.71 billion, a price-to-earnings ratio of -6.05 and a beta of 0.49. The company has a fifty day moving average of $100.33 and a 200 day moving average of $101.48. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its stake in shares of Mirum Pharmaceuticals by 14.5% in the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company's stock valued at $641,764,000 after purchasing an additional 880,505 shares during the last quarter. Jupiter Topco LLC bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at approximately $691,672,000. BlackRock Inc. bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at approximately $513,945,000. William Blair Investment Management LLC purchased a new stake in Mirum Pharmaceuticals during the 2nd quarter valued at $164,453,000. Finally, Geode Capital Management LLC raised its holdings in Mirum Pharmaceuticals by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 1,062,926 shares of the company's stock valued at $83,975,000 after buying an additional 52,904 shares during the period.

Insiders Place Their Bets

In other news, CFO Eric Bjerkholt sold 6,001 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the sale, the chief financial officer directly owned 36,355 shares in the company, valued at approximately $3,631,864.50. This represents a 14.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the sale, the senior vice president owned 1,274 shares in the company, valued at $127,400. This represents a 96.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 126,220 shares of company stock valued at $13,181,004 in the last three months. Corporate insiders own 8.32% of the company's stock.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Atebrioz (zilurgisertib) for adults and patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder involving abnormal bone formation. The approval was supported by PROGRESS data showing a reduction in new heterotopic ossification lesion volume, giving Mirum a new commercial product alongside partner Incyte. FDA approves Atebrioz article
• Positive Sentiment: Mirum reported that investigational brelovitug met the primary endpoint in the Phase 3 AZURE-1 study in chronic hepatitis delta (HDV). The liver-infection therapy reduced virus levels in patients, strengthening the case for a potential future regulatory filing and expanding Mirum’s growth opportunities beyond its existing liver-disease portfolio. Reuters brelovitug study article
• Positive Sentiment: HC Wainwright raised its price target on MIRM from $140 to $195 and maintained a “Buy” rating, reflecting increased confidence following the clinical and regulatory updates. HC Wainwright price target article
• Neutral Sentiment: Management is discussing the AZURE-1 topline results with investors. Investors will likely focus on the complete efficacy, safety, and regulatory details before assigning full value to brelovitug. AZURE-1 results transcript
• Neutral Sentiment: Atebrioz places Mirum and Incyte in the competitive market for treatments targeting abnormal bone formation, including products being developed by larger pharmaceutical companies. Competitive treatment article

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on liver and gastrointestinal disorders. The company's medicines are intended to address serious conditions for which available treatment options are limited.

Mirum's lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor approved in the United States for the treatment of cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.